After several years of continuous research and development, notable breakthrough has been made in the field of cancer therapy with the advent of immunotherapy.
Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:
- Global TIGIT Inhibitor Market Dynamics
- Clinical Approaches to Target TIGIT
- Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders
- Number of TIGIT Inhibitor Drug In Trials
- TIGIT Inhibitors Trials By Phase, Company, Country, Indication
- Clinical Trials Adverse Events Scenario
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global TIGIT Inhibitor Market Future Outlook
Download Report:
After several years of continuous research and development, notable breakthrough has been made in the field of cancer therapy with the advent of immunotherapy. Since its entrance into the market, the treatment of cancer has been shifted from conventional cancer therapies to novel immunotherapeutic drugs, which is mainly attributed to their enhanced efficacy and specificity towards the cancer cell. The continuous research and development activities in this sector have led to identification of TIGIT as a potential immune checkpoint inhibitor. TIGIT indirectly suppresses T-cell activation and has high expression on multiple types of immune cells including Treg cells, activated T cells, and natural killer cells. Apart from this, the receptor is generally expressed in several malignancies and is associated with advanced disease and poor survival outcomes. Thus, researchers believed that anti-TIGIT therapy can emerge as next generation immune checkpoint inhibitor therapy which has the ability to overcome the limitations of conventional immunecheckpoint inhibitors.
Recently in 2021, US FDA has granted a Breakthrough Therapy designation (BTD) to first anti-TIGIT therapy, tiragolumab in combination with atezolizumab (Tecentriq) for the frontline treatment of patients with metastatic non – small cell lung cancer (NSCLC). This was on the basis of promising phase-II trial response enhanced anti-tumor activity when targeting both immune inhibitory receptors TIGIT and PD-L1, by potentially amplifying the immune response. Apart from this, Ociperlimab developed by BeiGene is also late stage anti-TIGIT therapy which is also present in phase-III clinical trials and is expected to enter the market by 2023.
The companies are rapidly investing in the clinical trials of anti-TIGIT therapy which suggests the promising future of these drugs in the management of cancer. Globally, there are more than 50 ongoing clinical trials which are evaluating the role of anti-TIGIT therapy in the management of several cancers. In January, 2022 BioThera Solutions announced that dosing has begun in Phase 1 clinical study to evaluate the pharmacokinetics, safety, and preliminary anti-tumor activity of BAT6021, a monoclonal antibody with enhanced ADCC targeting TIGIT in cancer cells. In addition, ITEOS Therapeutics also demonstrated promising preclinical data of EOS-448, anti-TIGIT therapy. The company is expected to initiate their clinical trials in 2022. The rising investments by pharmaceutical companies and large number of ongoing clinical trials will also propel the global anti-TIGIT immunotherapy market in forthcoming years.
In recent times, the pharmaceutical companies have adopted more collaborative way to design the novel drug. For instance in 2021, BeiGene announced an option, collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan. In addition, Coehrus Bioscience and Shanghai Junshi Bioscience announced that Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences’ TIGIT-targeted antibody, in the United States and Canada, expanding the companies’ 2021 immuno-oncology collaboration agreement.
As per our report findings, the global anti-TIGIT immunotherapy market market will be mainly driven by the rapid increase in the geriatric population which possesses significant risk of developing cancer. Moreover, the unavailability of effectively curing cancer drugs also demands for the development of targeted therapy which will also boost the market. The forthcoming years will witness new product launches, increasing investment, and rising initiatives by government to increase awareness about targeted cancer therapies in the market. These all factors will contribute to the growth of market during the forecast period.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities. The report also estimated the future market opportunity of anti-TIGIT therapy during the forecast period.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366